Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls

Cited by (272)

Items 101–200 of 272

1. DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury
   Jee Eun Lee, Jung Eun Kim, M. H. Lee, H. Song, J. Ghee, Young S. Kang, H. Min, Hyun Wook Kim, J. Cha, Jee Han et al. · 2016 · Laboratory Investigation
2. Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure
   Annalisa Sforza, Vera Vigorelli, Erica Rurali, Gianluca Lorenzo Perrucci, Elisa Gambini, Martina Arici, Alessia Metallo, Raffaella Rinaldi, Paolo Fiorina, Andrea Barbuti et al. · 2022 · Cardiovascular Diabetology
3. The pancreas: Bandmaster of glucose homeostasis
   Nathalie Jouvet, Jennifer L. Estall · 2017 · Experimental Cell Research
4. Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation
   Ai Q. Li, Liang Zhao, Teng F. Zhou, Meng Q. Zhang, Xiao M. Qin · 2014 · American Journal of Physiology-Cell Physiology
5. Exendin-4 Promotes Beta Cell Proliferation via PI3k/Akt Signalling Pathway
   Chaoxun Wang, Xiaopan Chen, Xiaoying Ding, Yanju He, Chengying Gu, Ligang Zhou · 2015 · Cellular Physiology and Biochemistry
6. Plasma Incretin Levels and Dipeptidyl Peptidase-4 Activity in Patients with Obstructive Sleep Apnea
   Takeshi Matsumoto, Norio Harada, Masanori Azuma, Yuichi Chihara, Kimihiko Murase, Ryo Tachikawa, Takuma Minami, Satoshi Hamada, Kiminobu Tanizawa, Morito Inouchi et al. · 2016 · Annals of the American Thoracic Society
7. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer
   Chalmer, Thor, Almdal, Thomas P, Vilsbøll, Tina, Knop, Filip K · 2015 · Expert Opinion on Drug Safety
8. Incretin actions and consequences of incretin‐based therapies: lessons from complementary animal models
   Simone Renner, Andreas Blutke, Elisabeth Streckel, Rüdiger Wanke, Eckhard Wolf · 2015 · The Journal of Pathology
9. The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
   Ioannis G. Lempesis, Jun‐Li Liu, Μaria Dalamaga · 2022 · Metabolism Open
10. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection
    Michael P. Dubé, Ellen S. Chan, Jordan E. Lake, Brett Williams, Jennifer D. Kinslow, ALAN L. LANDAY, Robert W. Coombs, Michelle Floris-Moore, Heather Jane Ribaudo, Kevin E. Yarasheski · 2018 · Clinical Infectious Diseases
11. Fucoidan from Ascophyllum nodosum Suppresses Postprandial Hyperglycemia by Inhibiting Na+/Glucose Cotransporter 1 Activity
    Xindi Shan, Xueliang Wang, Hao Jiang, Chao Cai, Jiejie Hao, Guangli Yu · 2020 · Marine Drugs
12. Glucagon‐like peptide‐1: The missing link in the metabolic clock?
    Patricia Lee Brubaker, Manuel Gil‐Lozano · 2016 · Journal of Diabetes Investigation
13. Pancreatic alpha cells in diabetic rats express active GLP-1 receptor: Endosomal co-localization of GLP-1/GLP-1R complex functioning through intra-islet paracrine mechanism
    Koji Nakashima, Hideaki Kaneto, Masashi Shimoda, Tomohiko Kimura, Kohei Kaku · 2018 · Scientific Reports
14. Glucose-Dependent Insulinotropic Polypeptide Receptor Deficiency Leads to Impaired Bone Marrow Hematopoiesis
    Mantelmacher, Fernanda Dana, Fishman, Sigal, Cohen, Keren, Pasmanik Chor, Metsada, Yamada, Yuichiro, Zvibel, Isabel, Varol, Chen · 2017 · The Journal of Immunology
15. Evidence for paracrine/autocrine regulation of GLP-1-producing cells
    Camilla Krizhanovskii, Qimin Zhang, Jens Juul Holst, Thomas Nyström, Åke Sjöholm · 2013 · American Journal of Physiology-Cell Physiology
16. Extracellular acidification stimulates GPR68 mediated IL-8 production in human pancreatic β cells
    Vikash Chandra, Angeliki Karamitri, Paul Richards, Françoise Cormier, Cyrille Ramond, Ralf Jockers, Mathieu Armanet, Olivier Albagli, Raphaël Scharfmann · 2016 · Scientific Reports
17. Effects of DPP ‐4 inhibitor linagliptin and GLP ‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
    Daisuke Yabe, Takashi Eto, Masanari Shiramoto, Shin Irie, Kenta Murotani, Yusuke Seino, Hitoshi Kuwata, Takeshi Kurose, Susumu Seino, Bo Åhrén et al. · 2016 · Diabetes Obesity and Metabolism
18. Leucine–glycine and carnosine dipeptides prevent diabetes induced by multiple low‐doses of streptozotocin in an experimental model of adult mice
    Tohid Vahdatpour, Ali Nokhodchi, Parvin Zakeri‐Milani, Mehran Mesgari Abbasi, Nasser Ahmadiasl, Hadi Valizadeh · 2019 · Journal of Diabetes Investigation
19. Positive effects of GLP‐1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes
    R. Charlotte Moffett, Steven Patterson, Nigel Irwin, Peter R. Flatt · 2014 · Diabetes/Metabolism Research and Reviews
20. GLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering?
    Julie A. Lovshin, David Z.I. Cherney · 2015 · Diabetes
21. Neoantigens and Microenvironment in Type 1 Diabetes: Lessons from Antitumor Immunity
    Maria J.L. Kracht, Arnaud Zaldumbide, Bart O. Roep · 2016 · Trends in Endocrinology and Metabolism
22. Immunohistochemical assessment of glucagon‐like peptide 1 receptor ( GLP‐1R ) expression in the pancreas of patients with type 2 diabetes
    Rikke Kaae Kirk, Charles Pyke, Matthias G. von Herrath, Jane Preuss Hasselby, Lars Pedersen, Pia G. Mortensen, Lotte Bjerre Knudsen, Ken T. Coppieters · 2017 · Diabetes Obesity and Metabolism
23. Methodological and metabolic considerations in the study of caffeine-containing energy drinks
    Jane Shearer · 2014 · Nutrition Reviews
24. Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition
    Elisabeth Streckel, Christina Braun-Reichhart, Nadja Herbach, Maik Dahlhoff, Barbara Keßler, Andreas Blutke, Andrea Bähr, Nicole Übel, Matthias Eddicks, Mathias Ritzmann et al. · 2015 · Journal of Translational Medicine
25. Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?
    Benjamin J. Lamont, Sofianos Andrikopoulos · 2014 · Journal of Endocrinology
26. Insulin Secretion Induced by Glucose-dependent Insulinotropic Polypeptide Requires Phosphatidylinositol 3-Kinase γ in Rodent and Human β-Cells
    Jelena Kolic, Aliya F Spigelman, Alannah M. Smith, Jocelyn E. Manning Fox, Patrick E. MacDonald · 2014 · Journal of Biological Chemistry
27. Impaired secretion of glucagon-like peptide 1 during oral glucose tolerance test in patients with newly diagnosed type 2 diabetes mellitus
    Xiaoli Wang, Fang Ye, Jun Li, Lingyun Zhu, Gang Ling Feng, Xiangyun Chang, Kan Sun · 2016 · Saudi Medical Journal
28. Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor
    Nicolai M. Doliba, Qin Liu, Changhong Li, Pan Chen, Chengyang Liu, Ali Naji, Franz M. Matschinsky · 2017 · Molecular Metabolism
29. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer’s and Parkinson’s disease
    Christian Hölscher · 2016 · Cardiovascular Endocrinology
30. Type 2 Diabetes and Vascular Endothelial Dysfunction
    Keiichi Torimoto, Yosuke Okada, Yoshiya Tanaka · 2018 · Journal of UOEH
31. Determination of progressive stages of type 2 diabetes in a 45% high-fat diet-fed C57BL/6J mouse model is achieved by utilizing both fasting blood glucose levels and a 2-hour oral glucose tolerance test
    Thuy Nguyen-Phuong, Sol Seo, B. Y. Cho, Jung-Ho Lee, Ji-Yun Jang, Chung‐Gyu Park · 2023 · PLoS ONE
32. Pro-α-cell-derived β-cells contribute to β-cell neogenesis induced by antagonistic glucagon receptor antibody in type 2 diabetic mice
    Xiaona Cui, Jin Bo Feng, Tianjiao Wei, Liangbiao Gu, Dandan Wang, Shan Lang, Kun Yang, Jin Yang, Hai Yan, Rui Wei et al. · 2022 · iScience
33. Regulation of Appetite, Satiation, and Body Weight by Enteroendocrine Cells. Part 2: Therapeutic Potential of Enteroendocrine Cells in the Treatment of Obesity
    Carsten Posovszky, Martin Wabitsch · 2015 · Hormone Research in Paediatrics
34. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet‐induced obese diabetic mice
    Finbarr P.M. O'Harte, MT Ng, Angela M. Lynch, John Michael Conlon, Peter R. Flatt · 2016 · Diabetes Obesity and Metabolism
35. Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
    Philip Raskin, Katherine Mann · 2014 · Diabetes Metabolic Syndrome and Obesity
36. Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice
    Giovanni Pacini, Bo Åhrén · 2017 · Physiological Reports
37. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
    Cooper, Mark E., van Raalte, Daniël H. · 2025 · Journal of Clinical Investigation
38. Efficacy of combination therapy with GABA, a DPP-4i and a PPI as an adjunct to insulin therapy in patients with type 1 diabetes
    Alexander Rabinovitch, Daniil Koshelev, Francisco Alejandro Lagunas‐Rangel, Liudmila Kosheleva, Tali Gavra, Helgi B. Schiöth, Shmuel Levit · 2023 · Frontiers in Endocrinology
39. Failure of the Brain Glucagon-Like Peptide-1-Mediated Control of Intestinal Redox Homeostasis in a Rat Model of Sporadic Alzheimer’s Disease
    Jan Homolak, Ana Babić Perhoč, Ana Knezović, Jelena Osmanović Barilar, Melita Šalković‐Petrišić · 2021 · Antioxidants
40. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials
    Daisuke Yabe, Anu Ambos, Bertrand Cariou, Lea Smircic Duvnjak, Marc Evans, Guillermo González-Gálvez, Jay Lin, Elena V. Nikonova, Pedro Luis de Pablos-Velasco, Jean‐François Yale et al. · 2016 · Journal of Diabetes and its Complications
41. Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts
    Tsung‐Ming Lee, Wei‐Ting Chen, Chen‐Chia Yang, Shinn‐Zong Lin, Nen‐Chung Chang · 2014 · Journal of Cellular and Molecular Medicine
42. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice
    Finbarr P.M. O'Harte, MT Ng, Angela M. Lynch, John Michael Conlon, Peter R. Flatt · 2016 · Molecular and Cellular Endocrinology
43. Triple drug therapy with GABA, sitagliptin, and omeprazole prevents type 1 diabetes onset and promotes its reversal in non-obese diabetic mice
    Francisco Alejandro Lagunas‐Rangel, Daniil Koshelev, Andrej Nedorubov, Liudmila Kosheleva, Vladimir Trukhan, Alexander Rabinovitch, Helgi B. Schiöth, Shmuel Levit · 2022 · Frontiers in Endocrinology
44. Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice
    Kunduziayi Aini, Daiju Fukuda, Kimie Tanaka, Yasutomi Higashikuni, Yoichiro Hirata, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Masataka Sata · 2019 · International Heart Journal
45. Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism
    Robert Hansford, Sophie A Buller, Anthony H. K. Tsang, Simon Benoit, Anna G. Roberts, Emmy Erskine, Thomas Brown, Valentina Pirro, Frank M. Reimann, Norio Harada et al. · 2025 · Cell Metabolism
46. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making
    Gerhard H. Scholz, Holger Fleischmann · 2014 · Therapeutic Advances in Endocrinology and Metabolism
47. Distinct inflammatory signatures of upper and lower body adipose tissue and adipocytes in women with normal weight or obesity
    Ioannis G. Lempesis, Nicole Hoebers, Yvonne P. G. Essers, Johan W. E. Jocken, Rosemary Dineen, Ellen E. Blaak, Konstantinos N. Manolopoulos, Gijs H. Goossens · 2023 · Frontiers in Endocrinology
48. Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
    Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, Alessandra Scatteia, Giandomenico Bisaccia, Salvatore De Rosa, Santo Dellegrottaglie, Chiara Bucciarelli‐Ducci, Daniele Torella, Isabella Leo · 2024 · Cardiovascular Diabetology
49. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points
    Daisuke Yabe, Hitoshi Kuwata, Ryota Usui, Takeshi Kurose, Yutaka Seino · 2015 · Current Medical Research and Opinion
50. Mahvash Disease: Pancreatic Neuroendocrine Tumor Syndrome Caused by Inactivating Glucagon Receptor Mutation
    Matthew B Lucas Victoria E Yuand · 2013 · Journal of Molecular and Genetic Medicine
51. Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists
    Neil Tanday, Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin · 2022 · Diabetes Obesity and Metabolism
52. β‐Cell glutamate signaling: Its role in incretin‐induced insulin secretion
    Norihide Yokoi, Ghupurjan Gheni, Harumi Takahashi, Susumu Seino · 2016 · Journal of Diabetes Investigation
53. Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys
    Qiaoli Cui, Yijing Liao, Yaojing Jiang, Xiaohang Huang, Weihong Tao, Quanquan Zhou, Anna Shao, Ying Zhao, Jia Li, Anran Ma et al. · 2020 · Journal of Endocrinology
54. Endogenous incretin levels and risk of first incident cancer: a prospective cohort study
    Amra Jujić, Christopher Godina, Mattias Belting, Olle Melander, Jens Juul Holst, Emma Ahlqvist, Maria F. Gomez, Peter M. Nilsson, Helena Jernström, Martin Magnusson · 2023 · Scientific Reports
55. The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss
    David S.H. Bell · 2014 · American Journal of Case Reports
56. Pathogenesis of Type 2 Diabetes Mellitus
    Ralph Anthony DeFronzo · 2018 · Endocrinology
57. The glucagon‐like peptide‐1‐based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys
    Denis Roy, Kristina D. Chadwick, Krystyna Tatarkiewicz, Carl LaCerte, Ann‐Marie Bergholm, Thomas Brodie, Raja S. Mangipudy, David G. Parkes, Michael J. Graziano, Tim Reilly · 2014 · Diabetes Obesity and Metabolism
58. Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes
    HARPREET SINGH BAJAJ, Badr A. Aljabri, Subodh Verma · 2018 · Current Opinion in Cardiology
59. Accumulation of 3-hydroxytetradecenoic acid: Cause or corollary of glucolipotoxic impairment of pancreatic β-cell bioenergetics?
    Nicolai M. Doliba, Qing Liu, Changhong Li, Jie Chen, Pan Chen, Chengyang Liu, David W. Frederick, Joseph A. Baur, Michael J. Bennett, Ali Naji et al. · 2015 · Molecular Metabolism
60. Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome
    Bahadır Öztürk, Ali Sami Gürbüz, İlker Durak, Serdar Öztürk · 2018 · Gynecological Endocrinology
61. Effects of GIP on regional blood flow during normoglycemia and hyperglycemia in anesthetized rats
    Xiang Gao, Andreas Lindqvist, Monica Sandberg, Leif Groop, Nils Wierup, Leif E. Jansson · 2018 · Physiological Reports
62. Glucose treatment of human pancreatic β-cells enhances translation of mRNAs involved in energetics and insulin secretion
    Albatoul Zakaria, Claire Berthault, Bertrand Cosson, Vincent A. Jung, Ida Chiara Guerrera, Latif Rachdi, Raphaël Scharfmann · 2021 · Journal of Biological Chemistry
63. Pancreatic regeneration: basic research and gene regulation
    Kenji Okita, Toru Mizuguchi, Shigenori Ota, Masayuki Ishii, Toshihiko Nishidate, Tomomi Ueki, Makoto Meguro, Yasutoshi Kimura, Naoki Tanimizu, Norihisa Ichinohe et al. · 2015 · Surgery Today
64. A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes
    Stuart A. Ross · 2014 · Current Medical Research and Opinion
65. The ANGPTL8 rs2278426 (C/T) polymorphism is associated with prediabetes and type 2 diabetes in a han Chinese population in Hebei province
    Hou, Guangsen, Tang, Yong, Ren, Luping, Guan, Yunpeng, Hou, Xiaoyu, Song, Guangyao · 2020 · International Journal of Endocrinology
66. Pancreatic Safety of Newer Incretin-Based Therapies: Are the “-tides” Finally Turning?
    Sridevi Devaraj, Anirban Maitra · 2014 · Diabetes
67. Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus
    Mary Angelyn Bethel, Wen Xu, Michael J. Theodorakis · 2014 · Diabetes Obesity and Metabolism
68. GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control
    Takashi Nomiyama, Toshihiko Yanase · 2016 · Expert Review of Endocrinology & Metabolism
69. Pancreatic Physiology and Functional Assessment
    Alessandro Paniccia, Richard David Schulick · 2017 · Elsevier eBooks
70. Altered pancreatic islet morphology and function in SGLT1 knockout mice on a glucose-deficient, fat-enriched diet
    Markus Mühlemann, Daniela Zdzieblo, Alexandra Friedrich, Constantin Berger, Christoph Otto, Heike Walles, Hermann Koepsell, Marco Metzger · 2018 · Molecular Metabolism
71. Pathogenesis of Type 2 Diabetes Mellitus
    Ralph Anthony DeFronzo · 2018 · Endocrinology
72. Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues
    Jean Claude Reubi · 2014 · Endocrine
73. Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders
    Yazhou Li, Kelli L. Vaughan, Yun Wang, Seong‐Jin Yu, Eun-Kyung Bae, Ian A. Tamargo, Katherine O. Kopp, David Tweedie, Cheng‐Chuan Chiang, Keith Thomas Schmidt et al. · 2024 · GeroScience
74. Classical and non-classical islet peptides in the control of β-cell function
    Dawood Khan, R. Charlotte Moffett, Peter R. Flatt, Andrei I. Tarasov · 2021 · Peptides
75. Pancreatic Blood Flow with Special Emphasis on Blood Perfusion of the Islets of Langerhans
    L. Jansson, P. Carlsson · 2019 · Comprehensive Physiology
76. Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits
    Daisuke Yabe, Hitoshi Kuwata, Masahiro Iwasaki, Yutaka Seino · 2015 · EMJ Diabetes
77. Does Incretin Agonism Have Sustainable Efficacy?
    Sok‐Ja Janket, Miyo K. Chatanaka, Dorsa Sohaei, Faleh Tamimi, Jukka H. Meurman, Eleftherios P. Diamandis · 2024 · Cells
78. Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
    Yining Xu, Daniel J. Drucker, Giovanni Traverso, Ana Beloqui · 2025 · Endocrine Reviews
79. The Regulation Role of the Gut-Islets Axis in Diabetes
    Songtao Yang, Jie Cao, Chuan Sun, Yuan Li · 2024 · Diabetes Metabolic Syndrome and Obesity
80. Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys
    John L. Vahle, Richard A. Byrd, Jamie L. Blackbourne, Jennifer A. Martin, Steven D. Sorden, Thomas E. Ryan, Thomas P. Pienkowski, Thomas J. Rosol, Paul W. Snyder, Günter Klöppel · 2015 · Toxicologic Pathology
81. Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes
    Viorica Ionut, Orison O. Woolcott, Hasmik Mkrtchyan, Darko Stefanovski, Morvarid Kabir, Malini S. Iyer, Huiwen Liu, Ana Valeria Castro, Qiang Wu, Josiane L. Broussard et al. · 2016 · PLoS ONE
82. Central GIP signaling stimulates peripheral GIP release and promotes insulin and pancreatic polypeptide secretion in nonhuman primates
    Paul B. Higgins, Robert E. Shade, Iram Pablo Rodriguez-Sanchez, Magdalena Garcia‐Forey, Maria Elizabeth Tejero, Venkata Saroja Voruganti, Shelley A. Cole, Anthony Gean Comuzzie, Franco B. Folli · 2016 · American Journal of Physiology-Endocrinology and Metabolism
83. The equine glucose-dependent insulinotropic polypeptide receptor: A potential therapeutic target for insulin dysregulation
    Murad H. Kheder, Martin N. Sillence, Litticia M. Bryant, Melody Anne de Laat · 2017 · Journal of Animal Science
84. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers
    Kensuke Fukui, Hiroyuki Kawahito, Noriyuki Wakana, Masakazu Kikai, Kensuke Terada, Keita Yamamoto, Daisuke Irie, Taku Kato, Sonoko Miyagawa, Hiroyuki Yamada · 2015 · Journal of the Renin-Angiotensin-Aldosterone System
85. Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes
    Kathleen H. Ang, Jennifer L. Sherr · 2017 · Expert Opinion on Drug Delivery
86. Effect of vegetable consumption with chewing on postprandial glucose metabolism in healthy young men: a randomised controlled study
    Kayoko Kamemoto, Yusei Tataka, Ayano Hiratsu, Chihiro Nagayama, Yuka Hamada, Koji Kurata, Michiko Chiyoda, Machi Ito, Masashi Miyashita · 2024 · Scientific Reports
87. Obesity Associated with Type 2 Diabetes Mellitus Is Linked to Decreased PC1/3 mRNA Expression in the Jejunum
    Francieli Rohden, Cintia S. Costa, Thaís Ortiz Hammes, Rogério Margis, Alexandre Vontobel Padoin, Cláudio Corá Mottin, Regina Maria Vieira da Costa Guaragna · 2014 · Obesity Surgery
88. Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis
    Teresa Mezza, Simona Moffa, Pietro Manuel Ferraro, Giuseppe Quero, Umberto Capece, Andrea Carfì, CHIARA MARIA ASSUNTA CEFALO, Francesca Cinti, Gian Pio Sorice, Flavia Impronta et al. · 2019 · The Journal of Clinical Endocrinology & Metabolism
89. Molecular mechanisms redirecting the GLP-1 receptor signalling profile in pancreatic β-cells during type 2 diabetes
    Morgane Roussel, Julia Mathieu, Stéphane Dalle · 2016 · Hormone Molecular Biology and Clinical Investigation
90. Grape Pomace Aqueous Extract (GPE) Prevents High Fat Diet-Induced Diabetes and Attenuates Systemic Inflammation
    Haiwen Li, John W. Parry, Sarah M. Weeda, Shuxin Ren, Thomas W. Castonguay, Tai Liang Guo · 2016 · Food and Nutrition Sciences
91. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose
    Hiroshi Nomoto, Kimihiko Kimachi, Hideaki Miyoshi, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura, So Nagai, Takuma Kondo, Tatsuya Atsumi · 2017 · Endocrine Journal
92. Potential Effects of Hyperglycemia on SARS-CoV-2 Entry Mechanisms in Pancreatic Beta Cells
    Tara M. Michaels, M. Faadiel Essop, Danzil E. Joseph · 2024 · Viruses
93. Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues
    Marco Dal Molin, Haeryoung Kim, Amanda L. Blackford, Rajni B Sharma, Michael Goggins · 2015 · Pancreas
94. Protein Extract of a Probiotic Strain of Hafnia alvei and Bacterial ClpB Protein Improve Glucose Tolerance in Mice
    Vasiliy A. Zolotarev, Vladimir O. Murovets, Сепп Анастасия Леонидовна, Egor A. Sozontov, Ekaterina A. Lukina, Raisa P. Khropycheva, Nina S. Pestereva, Irina Sergeevna Ivleva, Mouna El Mehdi, Emilie Lahaye et al. · 2023 · International Journal of Molecular Sciences
95. GPCR targets in type 2 diabetes
    Patricio Atanes, Shanta Jean Persaud · 2019 · Elsevier eBooks
96. G-protein-coupled receptor 40 agonist GW9508 potentiates glucose-stimulated insulin secretion through activation of protein kinase Cα and ε in INS-1 cells
    Takuya Hashimoto, Hideo Mogami, Daisuke Tsuriya, Hiroshi Morita, Shigekazu Sasaki, Tatsuro Kumada, Yuko Suzuki, Tetsumei Urano, Yutaka Oki, Takafumi Suda · 2019 · PLoS ONE
97. Hormonal Responses to Cholinergic Input Are Different in Humans with and without Type 2 Diabetes Mellitus
    Sara Chowdhury, Songyan Wang, Judit Dunai, Rachel Kilpatrick, Lauren Z. Oestricker, Michael Wallendorf, Bruce W. Patterson, Dominic N. Reeds, Burton M. Wice · 2016 · PLoS ONE
98. Management of Type 2 Diabetes Mellitus
    Kathleen Marie Dungan · 2015 · Elsevier eBooks
99. Regulation of Pancreatic Secretion
    Rodger A. Liddle · 2018 · Elsevier eBooks
100. Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354
     Tayla A. Rees, Ben Buttle, Zoe Tasma, Sung-Hyun Yang, Paul W. R. Harris, Christopher S. Walker · 2024 · Frontiers in Pharmacology